

PATENT



#3 0300
ATTORNEY DOCKET NO. DASI.005.00US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Philippe Pouletty *et al*

Serial No.: 10/057,791

Filed: January 23, 2002

For: New amphetamine derivatives, antibodies
against them and pharmaceutical
compositions containing them

) Examiner:

) Art Unit:

) INFORMATION DISCLOSURE
) STATEMENT TRANSMITTAL

BOX DD

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is:

- ☒ A Information Disclosure Statement.
- ☒ A PTO-1449.
- ☐ Copies of references _____ as listed on the PTO-1449.
- ☐ An International Search Report.
- ☒ Return postcard (postage prepaid).

CERTIFICATE OF FIRST-CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to the U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202

on 4/11/02
(Date)

Courtney Mayer
(Signature)

Courtney Mayer

1. ☒ This Information Disclosure Statement is filed before the later of:
 - ☒ three months from the filing date of this national application;
 - ☐ three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or
 - ☐ the mailing date of a first office action on the merits.

☒ In accordance with 37 C.F.R. § 1.97(b), no fee is required.
2. ☐ This Information Disclosure Statement is filed after the events noted in paragraph 2, but before either:
 - (1) a final action under 37 C.F.R. § 1.113; or
 - (2) a Notice of Allowance under 37 C.F.R. § 1.311.

☐ In accordance with 37 C.F.R. § 1.97(c) also enclosed is:

 - ☐ a fee under 37 C.F.R. § 1.17(p) in the amount of \$240; or
 - ☐ a certification as stated below.
3. ☐ This Information Disclosure statement is filed before the payment of the issue fee, but after either:
 - (1) a final action under 37 C.F.R. § 1.113; or
 - (2) a Notice of Allowance under 37 C.F.R. § 1.311.

☐ In accordance with 37 C.F.R. § 1.97(d) also enclosed is:

 - (1) A certification, as stated below;
 - (2) A Petition requesting consideration of the Information Disclosure Statement; and

- (3) The petition fee set forth in 37 C.F.R. § 1.17(i)(1) in the amount of \$130.

Certification

The undersigned also states:

- ☐ Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.

The fees indicated above are:

TOTAL FEES: \$


- ☐ A check including the amount of the above-indicated TOTAL FEES is attached.
- ☐ Please charge Deposit Account No. 18-0020 in the amount of: \$ _____.
- ☐ A check in the amount of \$ _____ is attached.
- ☒ No fee is required.
- ☒ The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 18-0020.
- ☒ Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17.
- ☒ A duplicate copy of this sheet is attached for accounting purposes.

PATENT

ATTORNEY DOCKET NO. DASL005.00US

Respectfully submitted,

Dated: April 10, 2002



Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

Rae-Venter Law Group, P.C.
PO Box 1898
Monterey, CA 93942-1898
Phone: (831) 648-3090
Facsimile: (831) 242-0137

BRV/cs

PATENT

ATTORNEY DOCKET NO. DASL005.00US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Philippe Pouletty *et al*

Serial No.: 10/057,791

Filed: January 23, 2002

For: New amphetamine derivatives, antibodies
against them and pharmaceutical
compositions containing them

) Examiner:

) Art Unit:

) INFORMATION DISCLOSURE
) STATEMENT

BOX DD

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is hereby submitted in accordance with 37 CFR 1.98 and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

Copies of references will be submitted under separate cover.

Applicant makes no representation that a complete search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material.

CERTIFICATE OF FIRST-CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to the U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202

on April 11, 2002
(Date)

Courtney Mayer
(Signature)

Courtney Mayer


PATENT

ATTORNEY DOCKET NO. DASL005.00US

The subject application is believed patentable over any of the above references.

Respectfully submitted,

Dated: April 10, 2002



Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

Rae-Venter Law Group, P.C.
PO Box 1898
Monterey, CA 93942-1898
Phone: (831) 648-3090
Facsimile: (831) 242-0137

BRV/cs

PATENT

DOCKET NO. DASL005.00US



COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 1 of 2In re the application of: Philippe Pouletty, *et al.*

Art Unit:

Serial No. 10/057,791

Examiner:

Filed: January 23, 2002

U.S. PATENT DOCUMENTS

Ref.	Examiner's	Document			Class/	Filing
<u>Desig.</u>	<u>Initials</u>	<u>Number</u>	<u>Date</u>	<u>Name</u>	<u>Subclass</u>	<u>Date</u>
A1		5,976,812	11/2/99	Huber, et al.		7/17/97
A2		5,470,997	11/28/95	Buechler, et al.		4/6/92
A3		5,135,863	8/4/92	Hu, et al.		12/23/88

PENDING U.S. PATENT DOCUMENTS

Ref.	Examiner's			
<u>Desig.</u>	<u>Initials</u>	<u>Document Number</u>	<u>Name</u>	<u>Filing Date</u>
B1		NONE		

FOREIGN PATENT DOCUMENTS

Ref.	Examiner's	Document			Class/	
<u>Desig.</u>	<u>Initials</u>	<u>Number</u>	<u>Date</u>	<u>Country</u>	<u>Subclass</u>	<u>Filing Date</u>
C1		NONE				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref.	Examiner's	
<u>Desig.</u>	<u>Initials</u>	
D1		Burgess C, et al., <i>Eur. Psychiatry</i> 2000, 15(5):287-294.
D2		Hiramatsu M, et al., <i>Pharmacol. Biochem. Behav.</i> 1989, 33:343-347.

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PATENT

DOCKET NO. DAS1.005.00US

COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 2 of 2

In re the application of: Philippe Pouletty, *et al.*

]

Art Unit:

Serial No. 10/057,791

]

Examiner:

]

Filed: January 23, 2002

D3

K. Aoki, Y. Kuroiwa, *J. Pharm. Dyn.* 1983, 6, 33-38.

D4

K.A.A Bymes-Blake, et al., *International Immunopharmacology* 1, 2001, 329-338.

D5

S. Inayama, et al., *Chem. Pharm. Bull.* 1977, 35, 838.

D6

S. Inayama, et al., *Chem. Pharm. Bull.* 28, 1980, 2779.

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.